ZNTL, US98943L1070

Zentalis Pharmaceuticals stock: Q3 loss widens as DENALI advances

Published on 11/20/2026 at 00:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zentalis Pharmaceuticals stock remains focused on azenosertib as DENALI Part 2c enrollment targets completion in November. Integrated results are expected in 2027.

Clinical milestones shape outlook

  • Zentalis expects DENALI Part 2c enrollment to finish in November and integrated topline results in the first half of 2027.
  • The company reported a third-quarter net loss of 28.815 million US dollars and held 228.893 million US dollars in cash, cash equivalents and marketable securities at September 30.
  • Azenosertib remains in development for Cyclin E1-positive platinum-resistant ovarian cancer and additional tumor types.
ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals reported third-quarter results on Monday, November 9, 2026, while outlining the next clinical milestones for azenosertib. The company expects enrollment in DENALI Part 2c to finish in November and an integrated topline readout from Parts 2a, 2b and 2c in the first half of 2027, according to the Zentalis Pharmaceuticals press release.

Clinical program moves toward readout

DENALI is a Phase 2 study of azenosertib in platinum-resistant ovarian cancer. Parts 2a and 2b have completed enrollment, while Part 2c expands the study to patients previously treated with a taxane-containing regimen. Zentalis is also enrolling patients in the Phase 3 ASPENOVA trial and the MUIR Phase 1b combination study with bevacizumab.

The company plans to discuss DENALI results with the U.S. Food and Drug Administration in 2027 to assess an accelerated approval opportunity. ASPENOVA is intended to support a full approval pathway, subject to the clinical results and regulatory review.

Quarterly loss remains substantial

Zentalis posted a third-quarter net loss of 28.815 million US dollars, compared with 26.691 million US dollars a year earlier. The loss per share narrowed to 0.34 US dollars from 0.37 US dollars. Research and development expenses fell to 22.334 million US dollars from 22.950 million US dollars, while total operating expenses declined to 31.154 million US dollars from 33.734 million US dollars.

Cash, cash equivalents and marketable securities totaled 228.893 million US dollars at September 30, compared with 174.6 million US dollars at June 30. Zentalis said the balance should fund operating expenses and capital expenditure requirements into the first half of 2028.

Clinical oncology remains core focus

Zentalis Pharmaceuticals is a clinical-stage biotechnology company focused on oncology. Its main program is azenosertib, an oral WEE1 inhibitor being studied as a biomarker-driven treatment for ovarian cancer and in combination studies across additional tumor types. The company is based in the United States and is advancing both monotherapy and combination approaches rather than marketing an approved commercial product.

Zentalis Pharmaceuticals at a glance

  • Company: Zentalis Pharmaceuticals, Inc.
  • ISIN: US98943L1070
  • Ticker: ZNTL
  • Home exchange: Nasdaq Global Market
  • Focus: Clinical oncology and biomarker-driven drug development

The company operates in the US biotechnology market alongside the broader S&P 500 environment; see current market reports.

More news and analyses on Zentalis Pharmaceuticals stock.

Disclaimer...
en | US98943L1070 | ZNTL | boerse | 70538162 | bgmi